» Articles » PMID: 35262395

Comparison of the Performance of Two Galactomannan Detection Tests: Platelia Aspergillus Ag and Aspergillus Galactomannan Ag Virclia Monotest

Overview
Specialty Microbiology
Date 2022 Mar 9
PMID 35262395
Authors
Affiliations
Soon will be listed here.
Abstract

The use of nonculture-based biomarkers such as the determination of galactomannan is sought for the diagnosis of invasive aspergillosis. To investigate the comparative yield of two tests for the detection of galactomannan in patients with or without proven or probable invasive aspergillosis. Overall, 327 samples (327 patients) were analyzed in a retrospective/prospective study performed in 3 hospitals in Madrid, comparing the determination results in serum or bronchoalveolar lavage of two techniques for galactomannan detection, namely, Platelia Aspergillus Ag (Bio-Rad) and Aspergillus galactomannan Ag Virclia Monotest (Vircell S.L.), following the manufacturer's instructions. Both techniques can automate the process, but the second technique has the advantage of individual processing and assembly of each sample without the need for the additional expense of single-dose strips in controls. In total, 288 of the 327 tests performed showed concordant results between both techniques. The agreement between both methods was к = 0.722, and the correlation between indices was ρ = 0.718. Only 39 samples showed discordant results. In those 39 cases, there were 15 patients with proven or probable invasive aspergillosis criteria. For the samples with clinical criteria as a reference, the areas under the curve of the receiver operating characteristic (ROC) curve were 0.962 for Platelia and 0.968 for VirClia. The VirClia test has been proven to be an alternative for diagnosis due to its friendlier automated format than that of the usual Platelia routine test. The VirClia test also allows individual action and, therefore, a more immediate clinical response. Invasive mycoses are increasingly present in immunosuppressed or hospitalized patients with serious illnesses, leading to high rates of morbidity and mortality. Invasive aspergillosis is an infection caused, in a percentage greater than 50%, by the genus Aspergillus. It is vitally important to make an early diagnosis that leads to the application of antifungals in the initial stage of the infection. Therefore, tools are required to help with the early diagnosis of the infection. This comparative study of two enzyme immunoassays is based on the detection of galactomannan antigen in serum and bronchoalveolar lavage samples. A new design based on chemiluminescence and presented in an automated single-dose format is compared to a conventional ELISA technique marketed for years. The results obtained from the prospective and retrospective study indicate a high correlation and degree of agreement between both techniques, as well as in their diagnostic performance.

Citing Articles

Viral reactivations and fungal infections in nonresolving acute respiratory distress syndrome.

Maessen L, Boers L, Heylen J, van Someren Greve F, Wauters J, Bos L Eur Respir Rev. 2025; 34(175).

PMID: 39971398 PMC: 11836671. DOI: 10.1183/16000617.0153-2024.


Multicenter validation of a galactomannan chemiluminescence immunoassay for the diagnosis of pulmonary aspergillosis on serum of patients with hematological disease.

Lamberink H, Huygens S, Aerts R, Lagrou K, van Dijk K, Langerak D J Clin Microbiol. 2025; 63(2):e0105324.

PMID: 39835823 PMC: 11837514. DOI: 10.1128/jcm.01053-24.


Evaluation of a New Automated Mono-Test for the Detection of Galactomannan: Comparison of Galactomannan Ag VirCLIA Mono-Test with Platelia Ag ELISA Assay.

Lo Cascio G, Lepera V, Sorrentino A, Caleca D, Gigante P, Tocci G J Fungi (Basel). 2024; 10(11).

PMID: 39590712 PMC: 11595404. DOI: 10.3390/jof10110793.


Serum antigen tests for the diagnosis of invasive aspergillosis: a retrospective comparison of five antigen assays and one beta-D-glucan assay.

Schub T, Klugherz I, Wagener J, Prattes J, Hoenigl M, Suerbaum S J Clin Microbiol. 2024; 62(12):e0095024.

PMID: 39494863 PMC: 11633112. DOI: 10.1128/jcm.00950-24.


Diagnostic Value of Serum Biomarkers for Invasive Aspergillosis in Haematologic Patients.

Montesinos I, Albichr I, Collinge E, Delaere B, Huang T, Bogaerts P J Fungi (Basel). 2024; 10(9).

PMID: 39330420 PMC: 11433095. DOI: 10.3390/jof10090661.


References
1.
Bart-Delabesse E, Basile M, Al Jijakli A, Souville D, Gay F, Philippe B . Detection of Aspergillus galactomannan antigenemia to determine biological and clinical implications of beta-lactam treatments. J Clin Microbiol. 2005; 43(10):5214-20. PMC: 1248458. DOI: 10.1128/JCM.43.10.5214-5220.2005. View

2.
Pfeiffer C, Fine J, Safdar N . Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis. 2006; 42(10):1417-27. DOI: 10.1086/503427. View

3.
Gorton R, White P, Bagkeris E, Cotterall D, Desai R, McHugh T . Improved Standardization of the Bio-Rad Platelia Aspergillus Galactomannan Antigen Sandwich Enzyme Immunoassay Using the DS2 (Dynex) Enzyme-Linked Immunosorbent Assay (ELISA) Processing System. J Clin Microbiol. 2015; 53(7):2072-8. PMC: 4473217. DOI: 10.1128/JCM.00157-15. View

4.
Li X, Zheng Y, Wu F, Mo D, Liang G, Yan R . Evaluation of quantitative real-time PCR and Platelia galactomannan assays for the diagnosis of disseminated Talaromyces marneffei infection. Med Mycol. 2019; 58(2):181-186. DOI: 10.1093/mmy/myz052. View

5.
Nucci F, Nouer S, Capone D, Nucci M . Invasive mould disease in haematologic patients: comparison between fusariosis and aspergillosis. Clin Microbiol Infect. 2018; 24(10):1105.e1-1105.e4. DOI: 10.1016/j.cmi.2018.05.006. View